• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Revvity Inc.

    5/30/25 8:00:26 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    SD 1 d927602dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

     

     

    Revvity, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Massachusetts   001-05075   04-2052042

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    77 4th Avenue, Waltham, Massachusetts   02451
    (Address of Principal Executive Offices)   (Zip Code)

    John L. Healy (781) 663-6900

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

      ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

      ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended      .

     

     
     


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 – Conflict Minerals Disclosure and Report

    The Conflict Minerals Report for the calendar year ended December 31, 2024, filed herewith as Exhibit 1.01, is available at www.revvity.com under “Social”.

    Item 1.02 – Exhibit

    Exhibit 1.01 – Conflict Minerals Report of Revvity, Inc. for the calendar year ended December 31, 2024.

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 – Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

    Item 3.01 – Exhibits

    Exhibit 1.01 – Conflict Minerals Report of Revvity, Inc. for the calendar year ended December 31, 2024.

     

    2


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

        REVVITY, INC.
    Date: May 30, 2025     By:  

    /s/ Joel S. Goldberg

        Joel S. Goldberg
        Senior Vice President, Administration, General Counsel and Secretary

     

    3

    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

    New software further strengthens Revvity's market-leading position in in vivo imaging while empowering scientists with faster, more reproducible insights Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. "Our Living Image Synergy AI software marks a significant leap forward in p

    9/29/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of 6.3% | The Insight Partners

    NEW YORK, Sept. 22, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global lab automation market is observing significant growth due to technological advancements, regulatory & quality compliance, and demand for efficiency & throughput. The report runs an in-depth analysis of market trends, key players, and future opportunities. The lab automation market generally comprises a vast array of types, equipment, applications, end users, and geography, which are expected to register strength in the coming years. Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com

    9/22/25 11:30:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

    Combination of Revvity's proprietary Pin-point platform and Profluent's AI-engineered proteins created to inspire accelerated development of novel gene editing therapies Revvity, Inc. (NYSE:RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit. This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing. Additionally, the Pin-point platform's modular design h

    9/22/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Gonzales Anita covered exercise/tax liability with 149 shares, decreasing direct ownership by 3% to 4,340 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Krakowiak Maxwell covered exercise/tax liability with 559 shares, decreasing direct ownership by 4% to 12,217 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:14 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Michas Alexis P sold $44,505 worth of shares (500 units at $89.01) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/28/25 4:05:04 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity upgraded by UBS with a new price target

    UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

    5/1/25 7:42:49 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Bernstein with a new price target

    Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

    1/10/25 8:41:17 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity upgraded by BofA Securities with a new price target

    BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

    12/13/24 8:43:02 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    8/5/25 4:10:32 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    7/28/25 7:12:47 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 11-K filed by Revvity Inc.

    11-K - REVVITY, INC. (0000031791) (Filer)

    6/20/25 2:18:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

    Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

    9/2/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

    7/24/25 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials